Preliminary Program
Session times on those days will not be finalized until the overall program schedule is completed.
Program Tracks (Please click each Track for detailed program information) |
Track 2: Breakthroughs in Cancer Prognostics and Diagnostics |
Track 5: Novel Approaches to Cancer Therapeutics
Track 5-1: Immuno-Oncology & Immunotherapy
| Time: May 15, 2019 (Wednesday) Place: Momoyama, 4th Floor |
|
|
Chair |
Dr. Tapan K. Bera, Associate Scientist, Laboratory of Molecular Biology, National Cancer Institute, USA |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Recombinant Immunotoxins Targeting B Cell Maturation Antigen is Cytotoxic to Myeloma Cell Lines and Myeloma Cells from Patients |
|
14:00-14:25 |
Title: Selection and Development of Potent T Cell Receptors for Cancer Immunotherapy |
|
14:25-14:50 |
Title: Genetic and Molecular Profiling of ICOS hi CD4 T Cells Demonstrates Clonal Expansion of Th1 Effector Cells Following Vopratelimab (JTX-2011) Treatment in Subjects with Solid Tumors |
|
14:50-15:15 |
Title: Development of Immunomodulatory Vaccines (T-win®) |
|
15:15-15:40 |
Title: DCE-MR Imaging Biomarker of Bevacizumab Response in Glioblastoma - A Xenograft Study |
Track 5-2: Advanced Targeted Therapy and Personalized Therapy for Cancer
| Time: May 16, 2019 (Thursday) Place: Suehiro, 4th Floor |
|
|
Chair |
Dr. Robyn A. Lindley, Associate Professor, The Victorian Comprehensive Cancer Centre, University of Melbourne, Australia |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Molecular Mechanism that Controls Expression of GGAA-Motif Containing Promoter-Driven Genes |
|
14:00-14:25 |
Title: Improved Platform for Breast Cancer Circulating Tumor Cell Enrichment and Characterization with Next-Generation Sequencing Technology
Dr. Catalin Mihalcioiu, Assistant Professor, McGill University Health Centre, Canada |
|
14:25-14:50 |
Title: Combination Treatment Comprising Thermal Therapy and Chemoterapy Using Drug-Contained Gold Nanorods |
|
14:50-15:15 |
Title: The Identification of Cancer Progression Associated Signatures (C-PAS) for High Risk Patient Stratification
Dr. Robyn A. Lindley, Associate Professor, The Victorian Comprehensive Cancer Centre, University of Melbourne, Australia |
|
15:15-15:30 |
Coffee Break |
| 15:30-15:55 | Title: Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management Dr. Peihan Kao, Chang Gung Memorial Hospital, Taiwan |
| 15:55-16:20 | Title: CXCL14, A Unique Multistep Tumor Suppressing Chemokine, Regulates Expression of Stem Cell Factors Dr. Ryu-Ichiro Hata, Professor, Molecular Biology at Kanagawa Dental College, Japan |
| 16:20-16:45 | Title: The tHERApeutic Potential of HERA-CD40L in Immunologic Cancer Treatment Dr. Christian Merz, Head of Cellular Analytics, Apogenix AG, Germany |
| 16:45-17:10 | Title: Benefit to Sequential Treatment with Targeted Therapy and Immunotherapy of a BRAF V600E and PD-L1 Positive Metastatic NSCLC Dr. Annia M. Martial, Assistant Professor, University of Illinois – Peoria Campus, USA |
| 17:10-17:35 |
Tile: CANscript™: A Phenotypic-based, Tumor Modeling Platform for Oncology & Immuno-oncology Drug Discovery and Development |
Track 5-3: Drug Discovery, Design, and Delivery (Part I)
|
Time: May 16, 2019 (Thursday) |
|
|
Chair |
Dr. Ioannis Papasotiriou, Medical Director, RGCC International GmbH, Switzerland |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Innovations in Drug Development through Transcriptomics Analysis of Liquid Biopsies and Exosome Utility Dr. Ioannis Papasotiriou, Medical Director, R.G.C.C. International GmbH, Switzerland |
| 14:00-14:25 | Title: Targeting Prostate Cancer by Using AKR1C3 Inhibitors Designed by a Bioisosteric Approach Dr. Donatella Boschi, Associate Professor, University of Turin, Italy |
|
14:25-14:50 |
Title: Targetting Intracellular Calcium Signalling in Cancer Chemotherapy |
|
14:50-15:15 |
Title: Hypericin – Prospective Anticancer Drug and its Interactions with Important Bio Macromolecules as Studied on the Molecular Level |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: UD-017, a Novel Highly Selective and Orally Active CDK7 Inhibitor, Shows a Significant Anticancer Activity in Patient-Derived Cancers
Mr. Shigeru Ushiyama, Chief Senior Researcher & Deputy General Manager, Drug Discovery and Pharmacology Group, Pharmaceutical Research Lab., Ube Industries, Ltd., Japan |
|
15:55-16:20 |
Title: Ambiguous Roles Played by RAP GTPase in Normal and Tumor Cells |
|
16:20-16:45 |
Title: A New Possibility on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation Using Potent and Innovative Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors |
|
16:45-17:10 |
Title: Novel Class of Agents for Cancer Chemotherapy |
Track 5-3: Drug Discovery, Design, and Delivery (Part II)
|
Time: May 17, 2019 (Friday) |
|
|
Chair |
Dr. Tseten Y Jamling, V. P. of Research and Development, Hera BioLabs, USA |
|
09:00-09:05 |
Chair's Introduction |
| 09:05-09:30 |
Title: Renal Failure during Chemotherapy: Old Drugs-New Insights, New Drugs-Old Toxicities |
|
09:30-09:55 |
Title: Vitamin D-Induced Vitamin D Receptor Expression Induces Tamoxifen Sensitivity in MCF-7 Stem Cells via Suppression of Wnt/β-Catenin Signaling |
|
09:55-10:20 |
Title: Effect of Preparatory Procedures of an Ayurvedic Formulation Shataputi Abhrak Bhasma on Physico-Chemical Attributes, Immunomodulation and Invitro Anticancer Activity on Lung, Leukemia and Prostate Cancer Cell Lines |
|
10:20-10:45 |
Title: Extremely Active Resveratrol (XAR™) Significantly Upregulates Anti-Cancer Genes in Humans In Vivo |
|
10:45-11:00 |
Coffee Break |
| 11:00-11:25 |
Title: Small-Molecule Regulators of Epitransciptomic Enzymes as Potential Novel Anticancer Drugs |
| 11:25-11:50 |
Title: A Novel Rag2/Il2rg Double-Knockout Rat (SRG OncoRat) Enables Precision-Medicine Based Cancer Studies with Patient Derived Xenografts |
BIT Group Global Ltd.
Japan-China Business Co., Ltd.
日中商務株式会社
Dr. Vladimir Lazar
Chief Scientific and Operating Officer
WIN Consortium, France
Dr. Ashok Srivastava
Chief Executive Officer & Chief Medical Officer, ClinFomatrix, Cure Pharmaceuticals, Inc, USA
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2008-2019 BIT Congress Inc.